1026 related articles for article (PubMed ID: 26402148)
1. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
2. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
3. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).
Heeney MM; Abboud MR; Amilon C; Andersson M; Githanga J; Inusa B; Kanter J; Leonsson-Zachrisson M; Michelson AD; Berggren AR;
Contemp Clin Trials; 2019 Oct; 85():105835. PubMed ID: 31446143
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Moser BA; LaBell ES; Chigutsa E; Jakubowski JA; Small DS
Clin Pharmacokinet; 2018 Feb; 57(2):243-254. PubMed ID: 28578536
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease.
Reams SG; Messana L; Brown PB; Nanry K; Gunnell AE
Contemp Clin Trials; 2018 Jan; 64():88-94. PubMed ID: 29104118
[TBL] [Abstract][Full Text] [Related]
9. Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.
Heath LE; Heeney MM; Hoppe CC; Adjei S; Agbenyega T; Badr M; Masera N; Zhou C; Brown PB; Jakubowski JA; Dampier C
Clin Trials; 2017 Dec; 14(6):563-571. PubMed ID: 28743191
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Wun T; Soulieres D; Frelinger AL; Krishnamurti L; Novelli EM; Kutlar A; Ataga KI; Knupp CL; McMahon LE; Strouse JJ; Zhou C; Heath LE; Nwachuku CE; Jakubowski JA; Riesmeyer JS; Winters KJ
J Hematol Oncol; 2013 Feb; 6():17. PubMed ID: 23414938
[TBL] [Abstract][Full Text] [Related]
11. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Badawy SM
N Engl J Med; 2016 Jul; 375(2):185. PubMed ID: 27410931
[No Abstract] [Full Text] [Related]
13. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Rees DC
N Engl J Med; 2016 Jul; 375(2):185-6. PubMed ID: 27410930
[No Abstract] [Full Text] [Related]
14. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
[TBL] [Abstract][Full Text] [Related]
15. Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.
Nottage KA; Hankins JS; Faughnan LG; James DM; Richardson J; Christensen R; Kang G; Smeltzer M; Cancio MI; Wang WC; Anghelescu DL
Clin Trials; 2016 Aug; 13(4):409-16. PubMed ID: 27000103
[TBL] [Abstract][Full Text] [Related]
16. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM; Abboud MR; Githanga J; Inusa BPD; Kanter J; Michelson AD; Nduba V; Musiime V; Apte M; Inati A; Taksande AM; Andersson M; Åstrand M; Maklad N; Niazi M; Himmelmann A; Berggren AR
Blood; 2022 Sep; 140(13):1470-1481. PubMed ID: 35849650
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
19. Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease.
Fein DM; Avner JR; Scharbach K; Manwani D; Khine H
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27862905
[TBL] [Abstract][Full Text] [Related]
20. Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study.
Inusa BPD; Colombatti R; Rees DC; Heeney MM; Hoppe CC; Ogutu B; Hassab HM; Zhou C; Yao S; Brown PB; Heath LE; Jakubowski JA; Abboud MR
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31744266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
